Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres

• DOI: 10.3892/ol.2021.12813
• Publication Date: 2021-05-24T21:04:31Z
• Authors: Lu Xie; Jie Xu; Xin Sun; Xiaowei Li; Kuisheng Liu; Xin Liang; Zuli Zhou; Hongqing Zhuang; Kunkun Sun; Yiming Wu; Jin Gu; Wei Guo
• Keywords: Apatinib; Refractory (planetary science)

For osteosarcoma that progresses following first-line chemotherapy, prognosis remains poor although anti-angiogenesis tyrosine kinase inhibitors (TKIs) have been verified to prolong progression-free survival. Apatinib has led positive responses in the treatment of refractory osteosarcoma. However, it demonstrates only short-lived activity, and disease control rate musculoskeletal lesions is worse compared with pulmonary lesions. This failure partly overcome by addition ifosfamide etoposide (IE). The present study retrospectively activity apatinib + IE relapsed or two sarcoma centres China. included patients had received a combination 500 mg (orally) daily regimen (n=33) between June 3 2017 July 17 2020. tumour burden was considerable these patients: 16/33 (48.5%) Patients lung lesions, 31/33 (93.9%) progressed lines therapies at baseline. With median follow-up duration 28.4 [interquartile range (IQR), 16.1-38.3] months, 21/33 (63.6%) objective responses, event-free survival 11.4 (IQR, 6.7-18.4) months. overall time 19.8 13.1-30.6) At last follow-up, downstaging, all completely resected. multiple sites metastasis, demonstrated clinically meaningful antitumor delayed progression recurrent after chemotherapy. manageable toxicity deserves further investigation prospective trials.